Ken Griffin's position in CRISPR Therapeutics AG is currently worth $15.2 Million. That's 0.02% of their equity portfolio (925th largest holding). The first CRISPR Therapeutics AG trade was made in Q4 2017. Since then Ken Griffin bought shares 38 more times and sold shares on 29 occasions. The investor's estimated purchase price is $23.8 Million, resulting in a loss of 36%.